Subscribe to RSS
DOI: 10.1055/s-0038-1649572
A Variant of t-PA (T103N, KHRR 296-299 AAAA) that, by Bolus, Has Increased Potency and Decreased Systemic Activation of Plasminogen
Publication History
Received 12 December 1992
Accepted after revision 17 February 1993
Publication Date:
04 July 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/199302/lookinside/thumbnails/10-1055-s-0038-1649572-1.jpg)
Summary
In the accompanying paper, we reported that the properties of decreased plasma clearance rate, increased fibrin specificity, and resistance to inactivation by PAI-1 could be effectively combined in the t-PA variant T103N, KHRR 296-299 AAAA. In the current study we evaluated the in vivo efficacy of this variant as well as variants containing the individual mutations T103N and KHRR 296-299 AAAA. Plasma clearance and in vivo lysis of whole blood and platelet-rich clots were determined in a rabbit arterio-venous shunt model. The T103N containing variants were administered as an intravenous (i.v.) bolus. KHRR 296-299 AAAA and t-PA were infused i.v. over 90 min. The clearance rate of the KHRR 296-299 AAAA variant was similar to t-PA. However, the clearance of the T103N and T103N, KHRR 296-299 AAAA variants were 8 and 6-fold reduced, respectively. Potency of the variants relative to t-PA on whole blood clots ranged from 0.9 (T103N, KHRR 296-299 AAAA) to 1.7 (T103N). Relative potency on platelet-rich clots ranged from 2.4 (T103N) to 4.2 (T103N, KHRR 296-299 AAAA). Fibrinogen concentrations in rabbits 120 min after dosing with a 2.5 mg/kg bolus were: 24, 16, 82, and 77% of initial for t-PA; T103N; KHRR 296-299 AAAA; and T103N, KHRR 296-299 AAAA treatment groups, respectively. These results suggest that the T103N, KHRR 296-299 AAAA variant of t-PA, given as a bolus, could result in greater efficacy, particularly on refractory platelet-rich clots, without inducing the severe systemic lytic state produced by a bolus of a less fibrin specific variant.
-
References
- 1 Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda I, Bulkley BH, Robison AK, Hutter Jr. AM, Bell WR, Spadard Jr. JJ, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo controlled trial. Circulation 1984; 70: 1012-1017
- 2 Topol EJ, Califf RM, George BS, Keriakes DJ. Lee KL for the TAMI Study Group, Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. J Am Coll Cardiol 1988; 12: 24A-31A
- 3 Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Andersen L, Collen D. the TAMI Study Group. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 1989; 80: 1222-1230
- 4 TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Eng J Med 1989; 320: 618-627
- 5 Topol EJ, George BS, Kereiakes DJ, Candela RJ, Abbottsmith CW, Stump DC, Boswick JM, Stack RS, Califf RM. Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction. Am J Cardiol 1988; 61: 723-728
- 6 Neuhaus KL, Tebbe U, Gottwick M, Weber MAJ, Feuerer W, Haerer W, Praetorious F, Grosser KD, Huhmann W, Hoepp HW, Alber G, Sheikhzade A, Schneider B. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 1988; 12: 581-587
- 7 Neuhaus K-L, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989; 14: 1566-1569
- 8 Topol EJ. Ultrathrombolysis. J Am Coll Cardiol 1990; 15: 922-924
- 9 Tebbe U, Tanswell P, Seifried E, Feuerer W, Scholz K-H, Herrmann KS. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1989; 64: 448-453
- 10 Jang I-K, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920-928
- 11 Refino CJ, Pater C, Hultgren B, Hotchkiss AJ. Platelet dependent inhibition of thrombolysis by Activase® rt-PA in a rabbit arteriovenous shunt. Fibrinolysis 1990; 4 (Suppl. 03) 57 (abstr)
- 12 Levi M, Biemond BJ, van Zonneveld A-J, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-312
- 13 Hotchkiss A, Refino C, DeGuzman L, Rigter B, Eisert W. A new pan species model for the measurement of in vivo thrombolysis. Thromb Haemostas 1987; 58: 377 (Abstr)
- 14 Bliss CI. Confidence limits for measuring the precision of bioassays. Biometrics 1956; 12: 491-526
- 15 Mohler MA, Refino CJ, Chen SA, Chen AB, Hotchkiss AJ. D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thromb Haemostas 1986; 56: 160-164
- 16 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17: 237-240
- 17 Soria J, Soria C, Samama MA. A plasminogen assay using a chromogenic synthetic substrate: Results from clinical work and studies of thrombolysis. In: Chemical Fibrinolysis and Thrombolysis Vol 3. Davidson JF, MMS. Desnoyers PC. (eds) Raven Press; New York: 1978: 315-322
- 18 Tiefenbrunn AJ, Graor RA, Robinson AK, Lucas FV, Hotchkiss A, Sobel BE. Pharmacodynamics of tissue-type plasminogen activator characterized by computer assisted simulation. Circulation 1986; 73: 1291-1299
- 19 Hotchkiss A, Refino CJ, Leonard CK, O’Connor JV, Crowley C, McCabe J, Tate K, Nakamura G, Powers D, Levinson A, Mohler M, Spellman MW. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemostas 1988; 60: 255-261
- 20 Collen D, Stassen J, Larsen G. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 1988; 71: 216-219
- 21 Kalyan NK, Lee SG, Wilhelm J, Fu KP, Hum W-T, Rappaport R, Hartzell RW, Urbano C, Hung PP. Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties. J Biol Chem 1988; 263: 3971-3978
- 22 Fu KP, Lee S, Hum WT, Kalyan N, Rappaport R, Hetzel N, Hung PP. Disposition of a novel recombinant tissue plasminogen activator. Δ2-89 TPA, in mice. Thromb Res 1988; 50: 33-41
- 23 Refino CJ, Hotchkiss AJ, Higgins DL, Mohler MA. The pharmacokinetics and circulatory metabolism of a long half-life mutant of rt-PA. Fibrinolysis 1988; 2 (Suppl. 01) 30 (Abstr)
- 24 Larsen GR, Metzger M, Henson K, Blue Y, Horgan P. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 1989; 73: 1842-1850
- 25 Browne MJ, Carey JE, Chapman CG, Tyrrell AWR, Entwisle C, Lawrence GMP, Reavy B, Dodd I, Esmail A, Robinson JH. A tissue-type plasminogen activator mutant with prolonged clearance in vivo. J Biol Chem 1988; 263: 1599-1602
- 26 Lau D, Kuzma G, Wei C, Livingston DJ, Hsiung N. A modified human tissue plasminogen activator with extended half-life in vivo. Bio/Technology 1987; 5: 953-958
- 27 Lau D, Kuzma G, Wei C, Livingston DJ, Hsiung N. Erratum. Bio/ Technology 1988; 6: 734
- 28 Martin U, von Möllendorf E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemostas 1991; 66: 569-574
- 29 Anderson S, Keyt B. Variants of plasminogen activators and processes for their production. In: International Patent Application No. PCT-US89-01947. 1989
- 30 Ahem TJ, Morris GE, Barone KM, Horgan PG, Timony GA, Angus LB, Henson KS, Stoudemire JB, Langer-Safer PR, Larsen GR. Site-directed mutagenesis in human tissue plasminogen activator. J Biol Chem 1990; 265 (10) 5540-5545
- 31 Gardell SJ, Duong LT, Diehl RE, York JD, Hare TR, Register RB, Jacobs JW, Dixon RAF, Friedman PA. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989; 264: 17947-17952
- 32 Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang S, Tung J-S, Mark GE, Shebuski RJ. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991; 84: 244-253
- 33 Gardell SJ, Hare TR, Bergum PW, Cuca GC, O’Neill-Palladino L, Zavodny SM. Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator. Blood 1990; 76: 2560-2564
- 34 Cambier P, van de Werf F, Larsen GR. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. J Cardiovasc Pharmacol 1988; 11: 468-472
- 35 Wu Z, van de Werf F, Stassen T, Mattsson C, Pohl G, Collen D. Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model. J Cardiovasc Pharm 1990; 16: 197-203
- 36 Jackson CV, Crow VG, Craft TJ, Sundboom JL, Grinnell BW, Bobbitt JL, Burck PJ, Quay JF, Smith GF. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis. Circulation 1990; 82: 930-940
- 37 Martin U, Fischer S, Kohnert U, Opitz U, Rudolph R, Sponer G, Stern A, Strein K. Thrombolysis with an escherichia-coli-produced recombinant plasminogen activator (BM 06.22) in the rabbit model of jugular vein thrombosis. Thromb Haemostas 1991; 65 (05) 560-564
- 38 Martin U, Fischer S, Kohnert U, Rudolph R, Sponer G, Stern A, Strein K. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.22) in a canine model. J Cardiovasc Pharmacol 1991; 18: 111-119
- 39 Refino CJ, Hultgren B, Hollenbach S, Hotchkiss AJ. Comparison of a bolus and a infusion dose regimen of recombinant tissue-type plasminogen activator (rt-PA) on the rate of thrombolysis in the rabbit jugular vein model (RJVM). Thromb Haemostas 1987; 58(1): 235 (Abstr)
- 40 Stassen JM, Vanlinthout I, Kieckens L, Lijnen HR, Collen D. Thrombolysis with different rt-PA regimens in rabbits with experimental jugular vein thrombosis. Fibrinolysis 1990; 4 (Suppl. 03) 172 (Abstr)
- 41 Hofmann KJ, Mayer EJ, Schultz LD, Socher SH, Reilly CF. Purification and characterisation of recombinant rabbit plasminogen activator inhibitor-1 expressed in saccharomyces cerevisiae. Fibrinolysis 1992; 6: 263-272
- 42 Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatternd G, Robertson TL, Terrin ML. for the Timi investigators. Thrombolysis in myocardial infarction (TIMI) trial-phase 1: Hemorrhagic manifestations and changes in plasma fibrinogen and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11
- 43 Arnold AER, Brower RW, Collen D, van Es G-A, Lubsen J, Serruys PW, Simoons ML, Verstraete M. for the European Co-Operative Study Group for rt-PA. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plas-minogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. J Am Coll Cardiol 1989; 14: 581-588
- 44 Fennerty AG, Levine MN, Hirsh J. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1989; 95: 885-975
- 45 Munkvad S, Jespersen J, Gram J, Kluft C. Depression of factor XII-dependent fibrinolytic activity characterizes patients with early myocardial reinfarction after recombinant tissue-type plasminogen activator therapy. JACC 1991; 18: 454-458
- 46 Tanswell P, Heinzei G, Greischel A, Krause J. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated rat liver. J Pharmacol Exp Ther 1990; 255 (01) 318-324